Literature DB >> 8105760

Transluminal angioplasty of the subclavian artery in patients with internal mammary grafts.

L P Perrault1, M Carrier, G Hudon, L Lemarbre, Y Hébert, L C Pelletier.   

Abstract

From January 1987 to January 1992, 11 patients underwent percutaneous transluminal angioplasty (PTA) for the treatment of subclavian artery stenosis before or after coronary artery bypass grafting (CABG) using the internal mammary artery (IMA). There were 8 men and 3 women, with a mean age of 57 +/- 7 years. Four patients had PTA 1 to 4 months before undergoing CABG with IMA grafts, because of either asymptomatic supraclavicular murmurs or neurologic symptoms. Seven patients underwent PTA 2 to 37 months after CABG with IMA grafts, because of recurrent angina. Subclavian artery stenosis was on the left side in 9 patients, the right side in 1 patient, and bilateral in 1 patient. Ten PTA procedures were successful in 9 patients. All patients with post-CABG angina had reversal of the ischemia. There were three complications: one femoral artery thrombosis, one brachial plexus hematoma after an axillary approach, and one acute pulmonary edema after the procedure. Follow-up after PTA ranged from 1 to 60 months (mean, 38 +/- 17 months). Nine patients had no angina at follow-up and 2 had stable angina (class II) upon exertion. Upper-limb Doppler studies showed no evidence of restenosis in any of these patients at a mean follow-up of 38 months. Subclavian artery PTA is a useful alternative to IMA bypass grafting in patients with subclavian artery stenosis discovered preoperatively, and it is the treatment of choice for those presenting with post-CABG angina due to subclavian artery stenosis proximal to an IMA graft.

Entities:  

Mesh:

Year:  1993        PMID: 8105760     DOI: 10.1016/0003-4975(93)90357-n

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  1 in total

1.  Endovascular therapy of axillary artery disease with drug-coated balloon angioplasty.

Authors:  Subhi J Al'Aref; Rajesh V Swaminathan; Dmitriy N Feldman
Journal:  Proc (Bayl Univ Med Cent)       Date:  2017-10
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.